|Table of Contents|

Analysis of the effect of PD-1 inhibitor treatment on blood cell immune factors in patients with cervical malignancies

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 02
Page:
275-280
Research Field:
Publishing date:

Info

Title:
Analysis of the effect of PD-1 inhibitor treatment on blood cell immune factors in patients with cervical malignancies
Author(s):
WEI Yongqiang; YANG Zhijun; ZHAO Bingbing; LI Zhuang; ZHOU Lu; LI Kuina; YANG Meng; HUANG Zhijiong
Guangxi Medical University Cancer Hospital,Guangxi Nanning 530021,China.
Keywords:
cervical malignancies; PD-1 inhibitors; cellular immune factors
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2025.02.016
Abstract:
Objective:To investigate the relationship between the efficacy of PD-1 inhibitors in the treatment of cervical malignancies and changes in blood cellular immune factors.Methods:Approved by the Ethics Committee of Guangxi Medical University Cancer Hospital(Approval Number:LW2024142),the clinical data of 35 patients with advanced distant metastatic cervical cancer and 41 patients with recurrent cervical cancer who were diagnosed and treated with PD-1 inhibitors at the Guangxi Medical University Cancer Hospital from January 2020 to September 2022 were retrospectively analyzed.Based on Response Evaluation Criteria in Solid Tumor,patients were categorized into complete remission group,partial remission group,stable disease group or disease progression group.The changes and correlations of cell immune factors in the blood system of patients with different treatment effects before and after treatment were compared.Results:The proportion of blood CD3+ T cells in the partial remission group decreased significantly after treatment,and the difference was statistically significant (t=2.554,P＜0.05).In the stable disease group,the proportion of blood CD3+T cells decreased significantly after treatment (t=2.814,P＜0.05),and the proportion of CD3-CD56+CD16+T cells increased significantly (t=-2.427,P＜0.05).The proportion of CD3+CD4+ T cells in the blood system of patients in the disease progression group decreased significantly after treatment,and the difference was statistically significant (t=6.247,P＜0.05),while the proportion of other T cells had no statistical significance.Conclusion:After PD-1 inhibition therapy,the proportion of blood CD3+T cells decreased and the proportion of CD3-CD56+CD16+ T cells increased in patients with advanced cervical cancer with recurrence or distant metastasis were protective prognostic factors,while the proportion of CD3+CD4+ T cells decreased was a poor prognostic factor.

References:

［1］ SINGH D,VIGNAT J,LORENZONI V,et al.Global estimates of incidence and mortality of cervical cancer in 2020:a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative［J］.Lancet Glob Health,2023,11(2):e197-e206.
［2］ XIA ZE,LI Y,MING KH,et al.Association of L-selectin gene polymorphism with susceptibility to coronary heart disease［J］.Chinese Journal of Medicalgenetics,2007,24(2):173-176.
［3］ KUMAI T,LEE S,CHO HI,et al.Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses［J］.Cancer Immunol Res,2017,5(1):72-83.
［4］ GUO M,LIU M,BROOKS DG.Regulation and impact of tumor-specific CD4(+) T cells in cancer and immunotherapy［J］.Trends Immunol,2024,45(4):303-313.
［5］ VENKATESH H,TRACY SI,FARRAR MA.Cytotoxic CD4 T cells in the mucosa and in cancer［J］.Front Immunol,2023,14:1233261.
［6］ KENNEDY R,CELIS E.Multiple roles for CD4+ T cells in anti-tumor immune responses［J］.Immunological Reviews,2008,222(1):129-144.
［7］ MATSUZAKI J,TSUJI T,LUESCHER IF,et al.Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses［J］.Sci Rep,2015,5:14896-14903.
［8］ KRUSE B,BUZZAI AC,SHRIDHAR N,et al.CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours［J］.Nature,2023,618(7967):1033-1040.
［9］ BAESSLER A,VIGNALI D.T cell exhaustion［J］.Annu Rev Immunol,2024,42(1):179-206.
［10］ SHEVCHENKO I,BAZHIN AV.Metabolic checkpoints:Novel avenues for immunotherapy of cancer［J］.Front Immunol,2018,9:1816-1821.
［11］ VODNALA SK,EIL R,KISHTON RJ,et al.T cell stemness and dysfunction in tumors are triggered by a common mechanism［J］.Science,2019,363(6434):1417.
［12］ JOHNSTON RJ,COMPS-AGRAR L,HACKNEY J,et al.The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function［J］.Cancer Cell,2014,26(6):923-937.
［13］ CHAUVIN JM,PAGLIANO O,FOURCADE J,et al.TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients［J］.J Clin Invest,2015,125(5):2046-2058.
［14］ ANGELOSANTO JM,BLACKBURN SD,CRAWFORD A,et al.Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection［J］.J Virol,2012,86(15):8161-8170.
［15］ WHERRY EJ,KURACHI M.Molecular and cellular insights into T cell exhaustion［J］.Nat Rev Immunol,2015,15(8):486-499.
［16］ LU YJ,BARREIRA-SILVA P,BOYCE S,et al.CD4 T cell help prevents CD8 T cell exhaustion and promotes control of mycobacterium tuberculosis infection［J］.Cell Rep,2021,36(11):109696-109727.
［17］ MUNARI E,ZAMBONI G,LUNARDI G,et al.PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263［J］.Oncotarget,2018,9(54):30465-30471.
［18］ KYRYSYUK O,WUCHERPFENNIG KW.Designing cancer immunotherapies that engage T cells and NK cells［J］.Annu Rev Immunol,2023,41:17-38.
［19］ KIM N,KIM HS.Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells［J］.Front Immunol,2018,9:2041-2050.
［20］ CHEN Z,ZHU Y,DU R,et al.Role of regulatory B cells in the progression of cervical cancer［J］.Mediators Inflamm,2019,2019:6519427-6519434.

Memo

Memo:
广西医疗卫生适宜技术开发与推广应用项目(编号：S2021019)
Last Update: 1900-01-01